Cinacalcet HCl

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Hyperparathyroidism; Secondary, Renal

Conditions

Hyperparathyroidism; Secondary, Renal

Trial Timeline

Apr 19, 2017 → Sep 6, 2019

NCT ID

NCT03123406

About Cinacalcet HCl

Cinacalcet HCl is a approved stage product being developed by Kyowa Kirin for Hyperparathyroidism; Secondary, Renal. The current trial status is completed. This product is registered under clinical trial identifier NCT03123406. Target conditions include Hyperparathyroidism; Secondary, Renal.

What happened to similar drugs?

12 of 20 similar drugs in Hyperparathyroidism; Secondary, Renal were approved

Approved (12) Terminated (2) Active (8)

✅Paricalcitol + CalcifediolAbbVieApproved

✅Paricalcitol + Darbepoetin alfaAbbVieApproved

✅Alendronate 70mg weeklyMerckApproved

✅AMG 073AmgenApproved

✅DenosumabAmgenApproved

✅Sensipar® + Vitamin DAmgenApproved

✅Traditional Vitamin D Therapy + CinacalcetAmgenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03123406	Approved	Completed	Apr 19, 2017	Sep 6, 2019	Hyperparathyroidism; Secondary, Renal
NCT01460030	Phase 3	Completed	Nov 1, 2011	Feb 1, 2013	Parathyroid Carcinoma

Competing Products

20 competing products in Hyperparathyroidism; Secondary, Renal

See all competitors

Product	Company	Stage	Hype Score
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	35
KHK7580 + KRN1493	Kyowa Kirin	Phase 2/3	38
KHK7580	Kyowa Kirin	Phase 1	29
KHK7580	Kyowa Kirin	Phase 1/2	32
KHK7580	Kyowa Kirin	Phase 3	40
KHK7580	Kyowa Kirin	Phase 3	40
KHK7580 + Cinacalcet Hydrochloride	Kyowa Kirin	Phase 3	40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493	Kyowa Kirin	Phase 2	35
Paricalcitol + Calcitriol	AbbVie	Pre-clinical	18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo	AbbVie	Phase 3	40
Paricalcitol + Calcifediol	AbbVie	Approved	43
Paricalcitol + Darbepoetin alfa	AbbVie	Approved	43
Alendronate 70mg weekly	Merck	Approved	35
Etelcalcetide	Amgen	Phase 3	40
Cinacalcet + Placebo	Amgen	Phase 2	35
Cinacalcet + Placebo	Amgen	Phase 3	40
Etelcalcetide + Placebo	Amgen	Phase 1	29
Sensipar (Cinacalcet HCl)	Amgen	Phase 2	35
AMG 073 + Placebo	Amgen	Phase 3	40
cinacalcet	Amgen	Phase 3	40